Cancer-associated genetic alterations induce expression of tumor antigens which can activate CD8 + cytotoxic T cells
(Extended Data Fig. 3g,l) . When cultured ex vivo, tumoral IgA + B cells released soluble IgA (Extended Data Fig. 4a ). Oxaliplatin also increased serum IgA in both TRAMP and MCtumor models, but had little effect on serum IgG (Extended Data Fig. 4b-e) . Plasmocytic IgA + cells were found adjacent to α smooth muscle actin (αSMA)-expressing myofibroblasts (Fig. 3d) , which produce CXCL13 10 . Oxaliplatin-induced IgA + B cells from spleen and MC tumors expressed activation-induced cytidine deaminase (Extended Data  Fig. 4f,g ), suggesting recent class-switch recombination (CSR).
The IgA CSR is mainly induced by TGFβ together with CD40L, IL-21, IL-10 or IL-6 11 . Indeed, oxaliplatin increased the proportion of tumoral B cells containing phosphorylated SMAD2/3, and induced Tgfb1 mRNA in tumors ( Fig. 4o ,p). Tumoral CD19 + cells did not express CD5, a B regulatory (Breg) cell marker 12 (Extended Data Fig. 4q ). Oxaliplatin induced other immunoregulatory molecules, including Nos2, Arg1, IL-12p35 and IL-12p40, but no differences were observed between tumor-bearing WT and Jh -/-mice, although the latter expressed higher amounts of IL-12 (Extended Data Fig. 5a-d) . B cell deficiency or depletion had no significant effect on tumoral NK cells, myeloid CD11b + Gr1 + cells, macrophages or Treg (Extended Data Fig. 5e-i) . Thus, unlike mouse skin cancer, where B cells modulate therapeutic responsiveness through macrophages 13 , B cells in murine PC impede immunogenic chemotherapy by suppressing CTL activation.
Human PC samples (n=110) were analyzed for CD8 + and CD20 + cells (Extended Data Fig.  6a,b) . Comparison of matched normal and tumor tissues from 87 early stage PC (E-PC) patients indicated higher CD8 + and CD20 + counts in tumors (Extended Data Fig. 6c,d ). Patients with therapy-resistant PC (TR-PC) or metastatic PC (M-PC) exhibited reduced tumoral CD8 + cell density relative to E-PC patients, whose tumors contained fewer B cells than TR-PC and M-PC, in which B cells were most abundant (Extended Data Fig. 6e,f ). E-PC specimens displayed higher CD8/CD20 ratio than TR-PC and M-PC (Extended Data Fig.  6g ). Immunofluorescence (IF) and immunohistochemical (IHC) analyses of human PC specimens revealed IgA + cells in a scattered formation, frequently next to αSMA + myofibroblasts, especially in the high risk group ( Fig. 3l ; Extended Data Fig. 6h -j, and n). CD20 + B cells were both scattered and clustered in lymphoid follicle-like 16 areas (Extended Data Fig. 6b,k) . Human PC also contained IL-10-producing IgA + CD138 + cells and some IgA + cells were adjacent to CD8 + T cells and expressed little CD20 (Extended Data Fig. 6i k). 25% of IgA + cells in fresh prostatectomy specimens expressed IL-10 and were enriched in the malignant tissue portion (Extended Data Fig. 6l,m) . IgA + CD138 + plasmocytes exhibited higher density in TR-PC and M-PC than E-PC and patients with higher IgA + CD138 + cell counts showed lower CD8/CD20 ratio (Extended Data Fig. 6n-p) . Oncomine analysis of human IgA (IGHA1) mRNA revealed elevated IGHA1 mRNA in malignant versus healthy prostates in 11 of 15 datasets. Of these, 5 showed a significant increase (p < 0.05) and 3 showed a > 2-fold change. Results of one analysis 14 are presented (Extended Data Fig. 6q ) and fit earlier findings in mice 5, 6, 15 , suggesting that tumor infiltrating lymphocytes also control malignant progression and response to therapy in human PC.
Consistent with prior knowledge 11 and SMAD2/3 activation in PD-L1 + cells, TGFβR2 ablation in B cells (Tgfbr2 ΔB ) enhanced oxaliplatin-induced tumor regression, mildly decreased tumor-infiltrating, but not splenic, B cells and inhibited oxaliplatin-induced IgA + plasmocyte generation without affecting IgG1 + or IgG2a + cells ( Fig. 4a-c ; Extended Data Fig.7a-e) . IgA ablation also potentiated oxaliplatin responsiveness without reducing tumoral B cells (Fig. 4a,b) . Both TGFβR2 and IgA ablations, prevented induction of tumoral PD-L1 + or IgA + IL-10 + B cells by oxaliplatin, but barely affected IL-10 in B220 hi IgA -B cells (Extended Data Fig. 7f,g ). TGFβR2 ablation or IgA deficiency also increased tumoral CTL density, IFNγ-production and surface CD107 a expression by CD8 + T cells of oxaliplatintreated mice (Fig. 4e,f) . Suppressor B cells may attenuate T cell activation via PD-L1 16 . Treatment of mice bearing MC tumors with oxaliplatin plus anti-PD-L1, but not anti-PD-L1 alone, inhibited tumor growth, increased GrzB expression by effector T cells, downregulated PD-L1 expressionon IgA + cells, and reduced serum IgA, but not IgG (Extended Data Fig.  7h-m) . Reconstitution of tumor-bearing Jh -/-hosts with B cells lacking either PD-L1 or IL-10 failed to inhibit oxaliplatin-induced tumor regression ( Fig. 4g ; Extended Data Fig. 7n-p) . PD-L1 ablation did not affect IL-10 expression and IL-10 ablation had no effect on PD-L1 (Extended Data Fig. 10m ,n), indicating that both molecules are needed for plasmocytemediated immunosuppression.
We used oxaliplatin because of its well-described immunogenic properties, which are not exhibited by the related compound cisplatin 3, 4 . Both oxaliplatin and cisplatin induced apoptotic cell death but oxaliplatin was better in stimulating autophagy (Extended Data Fig.  8a,b) . Importantly, only LD oxaliplatin induced regression of MC tumors in Jh -/-mice, whereas LD cisplatin was ineffective, and only oxaliplatin increased the abundance of tumoral CD8 + and CD4 + cells (Extended Data Fig. 8c-e) . LD oxaliplatin did not increase intestinal permeability and had no effect on IgA production and other immune parameters in tumor-free WT or Tgfbr2 ΔB mice (Extended Data Fig. 8f-k) .
Immunogenic chemotherapy also potentiates the effectiveness of adoptively transferred T cells (ATCT). Immunogenic TRAMP-C2 cells 17 were inoculated into B cell-containing Tcrβ -/-mice followed by oxaliplatin treatment and ATCT (Extended Data Fig. 9a ). Bigger tumors in Tcrβ -/-relative to WT mice confirmed TRAMP-C2 immunogenicity (Extended Data Fig. 9b ). However, despite successful T cell take and elevated CD8 + count after oxaliplatin treatment, tumors were not rejected (Extended Data Fig. 9c-e) . TRAMP-C2 tumors were also raised in Rag1 -/-;OT-1 mice, which lack B cells and polyclonal T cells but harbor CD8 + cells directed against chicken ovalbumin (Ova) 18 . Adoptively transferred CD8 + cells expanded and expressed GrzB in Rag1 -/-;OT-1 hosts, especially after oxaliplatin treatment (Extended Data Fig. 9f-h ). Consequently, tumor growth was inhibited by ATCT combined with oxaliplatin (Extended Data Fig. 9i,j) . More dramatic results were obtained in TRAMP;Rag1 -/-mice transplanted with CFSE-labeled splenocytes from either naïve WT (B and T cell transfer) or Jh -/-(T cell transfer) mice (Extended Data Fig. 9k ). CD8 + cell proliferation in BM, spleens and prostates of transplanted mice indicated successful T cell take (Extended Data Fig. 9l,m) . Thirty days after lymphocyte transfer, prostate tumors were analyzed. Oxaliplatin caused modest tumor shrinkage in mice receiving T and B cells, but in mice receiving only T cells it induced complete regression (Fig. 5a,b) . Transplantation with T and B cells combined with oxaliplatin restored CD19 + cells in spleen and prostate and serum IgA and IgG, including IgA and IgG directed against SV40 T antigen, the TRAMP oncogene (Fig. 5c-e) , indicating a tumor-specific humoral response. Transferred B cells expressed TIM-1 (Extended Data Fig. 9o ), a molecule involved in regulation of IL-10 expression and tolerance induction 19 . B and T cell co-transplantation led to appearance of CD4 + and CD8 + cells in lymphoid organs, but T cell number was considerably lower in prostate tumors ( Fig. 5f ; Extended Data Fig. 9p-r) . However, transplantation with B celldeficient splenocytes caused robust T cell infiltration into prostate tumors ( Fig. 5f ; Extended Data Fig. 9r ). To confirm that IgA + B cells attenuate the response to immunogenic chemotherapy by inhibiting T cell activation, we raised MC tumors in Rag1 -/-mice and transplanted them with T cells from WT mice immunized with MC cell lysate, with or without naïve B cells from WT or Tgfbr2 ΔB spleens. In this case, oxaliplatin induced tumor regression and CTL activation only in mice receiving T cells, or T cells + TGFβR2-deficient B cells, which produced little IgA ( Fig. 5g-i ; Extended Data Fig. 10a-c) . Hence, only B cells that have undergone TGFβR signaling and IgA CSR suppress CTL activation.
Our results show that successful eradication of large prostate tumors by immunogenic chemotherapy requires removal of immunosuppressive IgA + plasmocytes that are present both in mouse and human PC. Spontaneous and transplantable PC models contain IgA + plasmocytes that strongly suppress CTL activation after treatment with oxaliplatin, an ICD inducer 4 . Although oxaliplatin causes regression of small tumors, it does not activate CTL or shrinks large prostate tumors, despite inducing DNA damage, unless tumor-infiltrating immunosuppressive B cells are removed. These B cells are IgA-producing plasmocytes that express PD-L1, IL-10 and Fas-L. Genetic analysis confirms that much of the immunosuppressive activity derives from IgA + PD-L1 + IL-10 + cells. Development of these cells, which differ from the LT-producing CD20 + B cells that infiltrate androgen-deprived prostate tumors and stimulate CRPC emergence through the IKKα-Bmi1 module 5, 6 , depends on TGFβR signaling. Nonetheless, CD20 + LT + B cells that are exposed to high TGFβ concentrations and antigen in the PC microenvironment after oxaliplatin treatment may eventually become IgA + plasmocytes. A likely source of TGFβ are αSMA + myofibroblasts that reside next to IgA + cells in oxaliplatin-treated mouse tumors and human PC samples 10 . Alternatively, LT-producing B cells may stimulate the IgA CSR, as signaling via LTβ receptor on gut stromal cells is required for IgA production 20 . Although the antiinflammatory and regulatory activities of intestinal IgA-producing cells 21 , as well as other plasmocytes 22 , are well known, this is the first time IgA + plasmocytes were found to suppress anti-tumor immunity.
IgA + plasmocytes within prostate tumors induce CD8 + cell exhaustion 2 and suppress antitumor CTL responses through PD-L1 and IL-10, either of which can induce anergy or exhaustion 2, 23 . Yet, B cells may regulate anti-tumor immunity by other mechanisms 24, 25 , including indirect control of T cell infiltration via macrophages 13 and IL-10 production by Breg cells 26 , although the latter only affect CD4 + T helper cells 24, 25 . Notably, IL-10-expressing IgA + cells are most abundant in therapy-resistant and metastatic human PC and circulating IgA is a well-established adverse prognostic indicator in PC 27 . We therefore suggest that elimination or inhibition of tumor infiltrating IgA + plasmocytes may be the key to successful immunotherapy of PC, as long as an immunogenic chemotherapeutic, such as oxaliplatin, is also used. Immunogenic chemotherapy may also enhance response rates to PD-1 or PD-L1 blockade in other malignancies, including bladder cancer and cutaneous melanoma where only 35% of the patients exhibit a response 28 .
Methods

Animal models
C57BL/6 and FVB control mice were from Charles River Laboratories and CD45.1 mice 29 were from the Jackson Laboratory, and all were bred at the University of California San Diego (UCSD) animal facility. C57BL/6-Tg(TRAMP)8247Ng/J (TRAMP mice) 30 _were backcrossed to the FVB strain for more than 10 generations. The median survival of TRAMP-FVB mice was 23 weeks compared to 52 weeks for TRAMP-C57BL/6 mice. TRAMP mice were crossed with B cell-deficient (Jh -/-) mice 31 , CTL-deficient (Cd8a -/-) mice 32 or Rag1 -/-mice, which lack both B and T cells 33 , all in the FVB-background. OT-I mice were obtained from Taconic 18 . Tgfbr2 F/F (FVB-background) mice were obtained from Dr. Hal Moses at Vanderbilt University 34 . Tcrb -/-, Cd19-Cre, Il10 -/-and CD45.1 mice were purchased from the Jackson Laboratory. IgA gene-deficient (Iga -/-) mice 35 were obtained from Baylor College of Medicine. Pdl1/2 -/-mice were obtained from Genentech (San Francisco, CA). Cd19-Cre and Iga -/-mice were backcrossed to the FVB strain for more than 10 generations. All mice were maintained in filter-topped cages on autoclaved food and water at the UCSD animal facility and all experiments were performed in accordance with UCSD and NIH guidelines and regulations.
Mouse treatment studies were "matched design control trials." Accordingly, mice were randomly chosen and paired based on sex (male), age (Extended Data Fig. 1a ) and tumor size. For transplanted tumor models, tumor size was defined by the median tumor volume (e.g. 400 mm 3 , for late treatments, Extended Data Fig. 1a,e) . For TRAMP transgenic tumor models, treatment decisions were made based on age and mice were randomly chosen including a control littermate. An identification code was assigned to each tumor-bearing mouse both in the transplanted and transgenic models, and the investigators were blinded to treatment allocation at the time of tumor volume measurement, autopsy and analysis.
The number of mice used in each experiment and the number of experiments are shown in Supplementary Table 1.
Flow cytometry and lymphocyte isolation
For lymphocytes isolated from spleen and lymph nodes, standard protocols using filters have been used. Lymphocytes were isolated from human blood using Ficoll-Paque PLUS (GE Healthcare Life Science) according to manufacturer's recommendations. For lymphocyte isolation from tumors (mouse and human), tumors were cut into small pieces and incubated in dissociation solution (RPMI medium supplemented with 5% FBS, collagenase type I (200 U/ml), collagenase type IV (200 U/ml), and DNase I (100 μg/ml) for 30 min at 37° C. After incubation, cell suspensions were passed through a 50 μm cell strainer and washed twice. For large tumors (≥ 0.7 g), hematopoietic cells were pre-enriched using density gradient centrifugation (Percoll or Ficoll), and red blood cells were lysed (RBC Lysis buffer, multispecies; eBioscience). For blocking of Fc-mediated interactions, mouse cells were preincubated with 0.5-1 μg of purified anti-mouse CD16/CD32 (93) 
Adoptive lymphocyte transfer
For adoptive T cell transfer (ATCT) CD8 + T cells were isolated from single cell suspensions, prepared from spleens and lymph nodes as described above, using CD8α-specific microbeads and MACS-columns (both Miltenyi Biotec GmbH, Bergisch Gladbach, Germany), and 5 × 10 6 CD8 + T cells were transferred intraperitoneally (i.p.; Extended Data 
Immune-mediated B cell depletion
B cells were depleted as previously described 38 . Mice were weekly injected (i.p.) with a mixture of monoclonal antibodies, each at 150 μg/mouse: rat anti-mouse CD19 (clone 1D3), rat anti-mouse B220 (clone RA36B2), and mouse anti-mouse CD22 (clone CY34). After 48 hrs, the mice were injected with a secondary antibody (mouse anti-rat kappa chain; GeneTex) at 150 μg/mouse. In addition, mice were injected weekly, but not on the same day, with 250 μg/mouse rat anti-mouse CD20 (Genentech). Rat anti-mouse IgG2a and IgG1 were used as isotype controls. Mice were treated for 3 weeks in total ( Fig. 1f; Extended Data Fig.  2j-p) .
Oncomine data analysis
In silico analysis of human IgA (IGHA1) mRNA expression was performed using 15 PC microarray gene datasets 14,39-52 from the Oncomine database (Compendia Biosciences; Ann Arbor, MI, USA; www.oncomine.org) 53 comparing a combined 126 carcinoma/ adenocarcinoma specimens to 30 normal (either benign, disease-free normal and/or normal adjacent) tissue specimens. Evaluation criteria were set as p < 0.05, fold change > 2.0, and gene rank in the top 10%.
Analysis of human specimens
Paraffin-embedded specimens from a total of 110 PC patients were integrated into a tissue microarray system (TMA) constructed at the Clinical Institute of Pathology at the Medical University of Vienna (MUV). All of the human specimens used for TMA construction were approved by the MUV Research Ethics Committee (1753/2014). The cohort included 87 patients with early PC (E-PC), 9 patients with therapy-resistant PC (TR-PC), and 15 patients with metastatic PC (M-PC). Patients' demographic and histopathological features are shown in Supplementary Table 2. TMA were designed to provide two cores of normal prostate tissue and four cores of PC tissue from each E-PC patient, and 3-6 cores of tumor tissue for each TR-PC and M-PC patient. Stained TMA slides were digitalized by virtual microscopy at 20 × magnification with a fixed light intensity and resolution into a bright-field image using the Nanozoomer (Hamamatsu) scanner. Computer-assisted image analysis of individual TMA core images was used to quantify the percentage of CD8 + and CD20 + immune reactive area (IRA%) as a proportion of the total digitized haematoxylin-stained region, as previously described 54 . For each PC patient, the mean continuous values of CD8 + and CD20 + IRA% in TMA cores without technical artifact for normal and tumor prostate tissue were calculated and used for subsequent statistical analysis. The presence of CD138 + and IgA + double immunoreactivity for plasma cells in the stromal compartment or directly contacting a cancer cell was semiquantitatively scored in TMA cores for each patient by an investigator who was blinded to the patients tumor features. A value of 0 was assigned to tissue cores without evidence of stromal CD138 + /IgA + double immunoreactive cells and a value of 1 was recorded when CD138 + /IgA + double immunoreactive cells were present in the stromal compartment. Furthermore, after approval from the UCSD institutional review board (IRB), whole tissue slides were subjected to immunohistochemical (IHC) analysis of αSMA + /IgA, CD8 + /IgA and IL-10 + /IgA double staining from a cohort of formalin-fixed, paraffin-embedded (FFPE) radical prostatectomy specimens. As previously described 55 , this cohort included up to 50 patients, which were selected based on known clinical outcome according to risk categories of low-, intermediate-and high-risk groups based on the D'Amico risk classification 56 .
Anonymized fresh prostatectomy and blood samples from consented human subjects, and de-identified clinical information were provided under the UCSD Moores Cancer Center Biorepository and Tissue Technology IRB approved protocol and provided to investigators (M.K., C.J.K., C.A.M.J., D.E.H.) with Cancer Sample Banking Committee approval. Fresh, de-identified samples of human prostate tissue and blood in 10 ml EDTA-coated tubes were collected from patients undergoing radical prostatectomy for clinically localized, intermediate or high risk PC, Gleason grade 3+4 or higher. A board-certified genitourinary pathologist (D.E.H.) collected samples of fresh prostate tumor and adjacent benign tissue, within 1 hr of radical prostatectomy, that were 5-10 mm in diameter.
Immunostaining
Tissues were embedded in Tissue Tek OCT (Sakura Finetek, Torrance, CA, USA) compound and snap-frozen. Tissue sections were fixed in cold acetone/methanol or 3% PFA for 3-10 min and washed with PBS. Slides were blocked with 1× PBS/1% normal donkey or goat serum for surface staining or 0.2% gelatin (from cold water fish skin; SigmaAldrich)/PBS/1% normal donkey or goat serum for intracellular staining for 30 min. Sections were incubated with primary antibodies for 1 or 12 hrs at RT or 4° C, respectively.
After washing with PBS, secondary antibodies were added for 1 hr at RT. As negative controls, samples were incubated with isotype-matched control antibodies or secondary antibodies only. After staining with DAPI, sections were covered with Vectashield Mounting Medium (Vector Laboratories, Burlingame, CA USA). TMA tissue slides from formalin-processed and paraffin-embedded tumor sections were processed for immunohistochemistry. After de-paraffinization and rehydration, sections were immersed in a pre-heated antigen retrieval water bath with a pH 
ELISA
Anti-SV40 Tag immunoglobulin ELISA was performed as described 57 . IgA and IgG ELISA kits were purchased from eBioscience, and used according to manufacturer's protocols. Tumoral single cell suspension has been prepared as described above in the flow cytometry section, and was washed 2-3 times with 1×PBS/2mM EDTA/2% FCS, to remove soluble IgA. Thereafter, about 3 × 10 6 cells/24-well were plated in either 10% FCS/DMEM or Hybridoma medium (Life Technology). After 24 hrs, the supernatants were analysed for IgA content. Media without cells were used as controls.
Treatment with chemotherapy or antibodies
Oxaliplatin was diluted in 5% dextrose and i.p. injected weekly at 6 mg/kg as indicated. Anti-PD-L1 antibody was i.v. injected at 10 mg/kg once, followed by 5 mg/kg bi-weekly. Mice were treated for three weeks for a total of 7 doses/animal.
Q-RT-PCR analysis
Total RNA was extracted using an RNeasy Plus kit (Qiagen). RNA was reverse transcribed using an IScript kit (Biorad). Q-RT-PCR was performed using Ssofast EvaGreens upermix (Biorad) on a Biorad CFX96 machine. Primer sequences are listed below and generally were obtained from the NIH qPrimerDepot (http://mouseprimerdepot.nci.nih.gov). The relative expression levels of target genes were measured in triplicates and normalized against the level of RPL32 expression. Fold-difference (as relative mRNA expression) was calculated by the comparative CT method (2 (Ct(RPL32-gene of interest)) ). 
Statistical analysis
Data are presented either averages ± S.E.M or median of continuous values and were analyzed by Students' t-test or Mann-Whitney-U, respectively, for comparison of two groups. Kruskal-Wallis test was used to compare three or more groups. Long-rank (MantelCox) tests were used to compare survival curves. Fisher's exact Chi-square P values were used to calculate statistical significance of categorical values between groups. Two tailed pvalues of ≤ 0.05 were considered significant. Unpaired t test-independent studies were used to determine the minimum sample sizes (StatsDirect Version 2.8.0). GraphPad PRISM software was used for statistical analyses.
Extended Data
Extended Data Figure 1 . Treatment schemes and characterization of tumors and mouse survival before and after treatment a, Early and late treatment schemes for TRAMP mice. b, TRAMP mice (n= 3-6/group) were subjected to early oxaliplatin treatment as described in (a) and prostate weights were determined at 14 weeks, one week after completion of 4 treatment cycles. Dashed red line indicates prostate weight of tumor-free controls (n=33 in total . eh, Patients were divided into three subgroups: E-PC (n=86); therapy-resistant-PC (TR-PC; n=9), and metastatic-PC (M-PC; n=15). e, CD8 + cell infiltration into tumor tissues of the different groups. f, CD20 + cell infiltration into tumor tissues of the different groups. g, The CD8 + /CD20 + ratio for the different groups. Each dot represents one patient. Line indicates the median value. Mann-Whitney test was used to calculate statistical significance between the two groups. Kruskal-Wallis test was used to calculate statistical significance between the three groups. h, IHC analysis of low risk (n=5) and high risk (n=5) human PC specimens using IgA (red) and αSMA (black). Nuclei were counterstained with hematoxylin. were treated with oxaliplatin (weekly). One day after 1 st oxaliplatin treatment, 5 × 10 6 T cells (negative selection) from WT mice immunized with MC cell lysate 10 were adoptively transferred into tumor-bearing mice (4-5 mice/group), alone or in combination with 5 × 10 6 B cells from WT or Tgfbr2 ΔB mice (purity 98%). After 2 more oxaliplatin cycles (3 weeks total), the mice were sacrificed and analyzed. Fig. 1g . f, MC tumors were inoculated into WT (left) or Cd8a -/-(right) mice. After 16 days, B cells were depleted with antibodies against CD19, CD20, CD22 and B220. Four days after first twice-weekly antibody treatment, mice received weekly oxaliplatin (n=4-7/group, total: 42), and sacrificed 3 weeks later. Tumor volumes were analyzed by Kruskal-Wallis test: P=0.007**. Results are means ± s.e.m. Mann-Whitney and t tests were used to determine significance indicated as *P, 0.05; **P, 0.01; ***P, 0.001. 
